Apellis Pharmaceuticals's total assets for Q4 2025 were $1.08B, an increase of 1.56% from the previous quarter. APLS total liabilities were $705.11M for the fiscal quarter, a 7.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.